StockMarketWire.com - Motif Bio said clinical trial supplies in the form of sterile ampoules of iclaprim have been manufactured. Following Quality Assurance release, these supplies will be shipped to clinical trial sites.

These activities enable Motif to remain on target to complete the two, previously announced Phase III ABSSSI trials in H2 2017.






Story provided by StockMarketWire.com